| Literature DB >> 34429391 |
Jianshu Chen1, Qiongying Wang2, Ying Pei2, Ningyin Li2, Junchen Han2, Jing Yu1,2.
Abstract
OBJECTIVE: The present study investigated the effects of free androgen index (FAI) on ambulatory blood pressure (ABP) and target organ function in postmenopausal hypertensive women.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34429391 PMCID: PMC8547744 DOI: 10.1097/GME.0000000000001835
Source DB: PubMed Journal: Menopause ISSN: 1072-3714 Impact factor: 3.310
General data about postmenopausal hypertension with different free androgen index levels
| FAI <0.15 ( | FAI 0.15-0.2 ( | FAI >0.2 ( | ||
| Age | 54.32 ± 3.72 | 54.35 ± 3.49 | 53.62 ± 3.57 | 0.18 |
| BMI (kg/m2) | 23.99 ± 3.24 | 24.36 ± 3.32 | 24.01 ± 3.20 | 0.32 |
| WHR | 0.84 ± 0.08 | 0.84 ± 0.06 | 0.84 ± 0.07 | 0.35 |
| Educational level (college degree or above), | 36 (39) | 26 (27) | 46 (48) | 0.17 |
| The duration of hypertension | 3.30 ± 2.65 | 3.58 ± 2.93 | 3.93 ± 2.39 | 0.18 |
| Family history of hypertension, | 64 (70) | 43 (44) | 57 (60) | 0.18 |
| Current antihypertensive drugs | ||||
| ACEI, | 13 (14) | 17 (17) | 21 (22) | 0.17 |
| ARB, | 32 (35) | 38 (39) | 36 (38) | 0.09 |
| Beta-blockers, | 6 (7) | 4 (4) | 13 (14) | 0.13 |
| CCB, | 62 (67) | 45 (46) | 74 (78) | 0.11 |
| Diuretic, | 25 (27) | 18 (18) | 17 (18) | 0.18 |
| TC (mmol/L) | 4.60 ± 0.81 | 4.73 ± 0.76 | 4.97 ± 0.74 | 0.02 |
| TG (mmol/L) | 1.47 (0.98-1.94) | 1.45 (1.05-1.98) | 1.36 (1.05-1.73) | 0.29 |
| LDL-C (mmol/L) | 2.56 ± 0.65 | 2.50 ± 0.57 | 2.63 ± 0.66 | 0.20 |
| BUN (mmol/L) | 4.71 ± 1.27 | 4.66 ± 1.24 | 4.62 ± 1.14 | 0.37 |
| CR (μmol/L) | 59.58 ± 10.88 | 61.77 ± 8.64 | 60.81 ± 8.60 | 0.18 |
| T (ng/dL) | 16.95 ± 3.06 | 21.13 ± 3.39 | 24.47 ± 3.34 | 0.00 |
| SHBG (nmol/L) | 130.81 ± 15.32 | 125.22 ± 18.29 | 116.96 ± 16.88 | 0.03 |
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; CR, creatinine; CCB, calcium channel blocker; FAI, free androgen index; LDL-C, low-density lipoprotein cholesterol; SHBG, sex hormone–binding globulin; T, testosterone; TC, total cholesterol; TG, triglyceride; WHR, waist-to-hip ratio.
Observed significance P < 0.05 compared with FAI <0.15 group.
Observed significance P < 0.05 compared with FAI 0.15-0.2 group.
Comparison of 24-hour ambulatory blood pressure in postmenopausal hypertensive women
| FAI<0.15 ( | FAI 0.15-0.2 ( | FAI >0.2 ( | Adjusted | |
| Daytime mean SBP (mmHg) | 140.07 ± 10.70 | 144.42 ± 11.21 | 168.11 ± 14.85 | 0.03 |
| Daytime mean DBP (mmHg) | 86.20 ± 11.64 | 84.54 ± 10.49 | 83.66 ± 10.02 | 0.09 |
| Nighttime mean SBP (mmHg) | 136.62 ± 15.90 | 134.43 ± 13.80 | 133.34 ± 15.24 | 0.10 |
| Nighttime mean DBP (mmHg) | 79.65 ± 12.31 | 78.47 ± 8.69 | 76.11 ± 10.82 | 0.03 |
| 24-h mean SBP (mmHg) | 137.73 ± 9.90 | 141.19 ± 10.44 | 145.21 ± 11.84 | 0.00 |
| 24-h mean DBP (mmHg) | 83.79 ± 9.64 | 82.92 ± 9.31 | 81.58 ± 9.51 | 0.09 |
| 24-h SBP CV (%) | 12.05 ± 2.86 | 13.24 ± 3.54 | 14.59 ± 4.50 | 0.00 |
| 24-h DBP CV (%) | 13.92 ± 3.14 | 14.21 ± 3.30 | 14.40 ± 3.56 | 0.17 |
| 24-h SBP SD | 16.66 ± 4.16 | 18.63 ± 5.01 | 21.08 ± 6.49 | 0.00 |
| 24-h DBP SD | 11.55 ± 2.65 | 11.74 ± 2.72 | 11.60 ± 2.61 | 0.24 |
| 24-h SBP ARV | 11.40 ± 1.13 | 14.49 ± 1.11 | 18.46 ± 3.74 | 0.00 |
| 24-h DBP ARV | 5.09 ± 1.27 | 6.22 ± 0.79 | 7.65 ± 1.37 | 0.00 |
ARV, average real variation; DBP, diastolic blood pressure; CV, coefficient of variation; FAI, free androgen index; SBP, systolic blood pressure; SD, standard deviation.
Observed significance P < 0.05 compared with FAI <0.15 group.
Observed significance P < 0.05 compared with FAI 0.15-0.2 group.
Comparison of target organ damage in postmenopausal hypertensive women
| FAI <0.15 ( | FAI 0.15-0.2 ( | FAI >0.2 ( |
| |
| Proteinuria, | 0 (0) | 1 (1) | 3 (3) | 0.08 |
| CAVI (left) | 7.02 ± 0.76 | 7.57 ± 0.82 | 8.75 ± 0.95 | 0.00 |
| CAVI (right) | 7.04 ± 0.53 | 7.88 ± 0.49 | 8.67 ± 0.72 | 0.00 |
| LVMI | 67.97 ± 9.88 | 84.86 ± 4.52 | 98.43 ± 1.29 | 0.00 |
CAVI, cardio-ankle vascular index; FAI, free androgen index; LVMI, left ventricular mass index.
Observed significance P < 0.05 compared with FAI <0.15 group.
Observed significance P < 0.05 compared with FAI 0.15-0.2 group.
FIG. 1Scatter diagram of the correlation between FAI and 24-hour SBP ARV and 24-hour DBP ARV in postmenopausal hypertensive women. (A) The correlation between FAI and 24-hour SBP ARV was established and (B) the correlation between FAI and 24-hour DBP ARV was identified in postmenopausal hypertensive women. ARV, average real variation; DBP, diastolic blood pressure; FAI, free androgen index; SBP, systolic blood pressure.
Multivariable regression analysis of free androgen index, left ventricular mass index, and cardio-ankle vascular index in postmenopausal hypertension
| Regression coefficient and 95% CI |
| |
| LVMI | ||
| Model 1 | 18.212 (16.180-20.243) | <0.001 |
| Model 2 | 18.388 (16.338-20.438) | <0.001 |
| Model 3 | 17.643 (15.482-19.795) | <0.001 |
| CAVI | ||
| Model 1 | 9.099 (7.665-10.533) | <0.001 |
| Model 2 | 8.947 (7.482-10.413) | 0.003 |
| Model 3 | 8.983 (7.422-10.524) | 0.008 |
Model 1: no adjustment; Model 2: adjusted for age, BMI, the course of hypertension, family history of hypertension, current antihypertensive drug, and serological indexes; Model 3: Model 1+ Model 2+ the 24-hour mean systolic blood pressure + the 24-hour mean diastolic blood pressure.
BMI, body mass index; CAVI, cardio-ankle vascular index; FAI, free androgen index; LVMI, left ventricular mass index.
Multivariable regression analysis of sex hormone–binding globulin: left ventricular mass index and cardio-ankle vascular index in postmenopausal hypertension
| Regression coefficient and 95% CI |
| |
| LVMI | ||
| Model 1 | −0.239 (−0.349 to −0.129) | <0.001 |
| Model 2 | −0.226 (−0.336 to −0.115) | <0.001 |
| Model 3 | −0.198 (−0.306 to −0.091) | <0.001 |
| CAVI | ||
| Model 1 | −0.014 (−0.021 to −0.007) | <0.001 |
| Model 2 | −0.013 (−0.020 to −0.006) | <0.001 |
| Model 3 | −0.009 (−0.016 to −0.003) | <0.001 |
Model 1: no adjustment; Model 2: adjusted for age, BMI, the course of hypertension, family history of hypertension, current antihypertensive drug, and serological indexes; Model 3: Model 1 + Model 2 + the 24-hour mean systolic blood pressure + the 24-hour mean diastolic blood pressure.
BMI, body mass index; CAVI, cardio-ankle vascular index; LVMI, left ventricular mass index; SHBG, sex hormone−binding globulin.
Multivariable regression analysis of free androgen index and 24-hour systolic blood pressure average real variation, 24-hour diastolic blood pressure average real variation in postmenopausal hypertension
| Related factor (FAI) | 24-h SBP ARV | 24-h SBP CV | 24-h SBP SD | 24-h DBP ARV | 24-h DBP CV | 24-h DBP SD |
| β | 0.426 | 0.204 | 0.211 | 0.642 | 0.199 | 0.232 |
| 0.001 | 0.515 | 0.489 | 0.044 | 0.537 | 0.473 | |
| Regression Coefficient | 20.416 | 11.767 | 17.794 | 16.539 | 9.719 | 9.202 |
| 95% CI | 8.143-32.688 | −23.822 to 47.356 | −32.840 to 68.482 | 0.472-32.607 | −21.265 to 40.704 | −16.043 to 34.447 |
Adjusted for age, body mass index (BMI), the course of hypertension, family history of hypertension, current antihypertensive drug, and serological indexes in multivariable regression model.
ARV, average real variation; CV, coefficient of variation; DBP, diastolic blood pressure; FAI, free androgen index; SBP, systolic blood pressure; SD, standard deviation.
Multivariable regression analysis of sex hormone–binding globulin and 24-hour systolic blood pressure average real variation, 24-hour diastolic blood pressure average real variation in postmenopausal hypertension
| Related factor (FAI) | 24-h SBP ARV | 24-h SBP CV | 24-h SBP SD | 24-h DBP ARV | 24-h DBP CV | 24-h DBP SD |
| β | −0.102 | −0.002 | −0.018 | −0.199 | 0.045 | 0.052 |
|
| 0.048 | 0.972 | 0.763 | 0.001 | 0.728 | 0.406 |
| Regression coefficient | −0.022 | 0.000 | −0.006 | −0.018 | 0.008 | 0.008 |
| 95% CI | −0.044 to 0.000 | −0.027 to 0.026 | −0.044 to 0.032 | −0.029 to −0.008 | −0.014 to 0.031 | −0.011 to 0.026 |
Adjusted for age, body mass index (BMI), the course of hypertension, family history of hypertension, current antihypertensive drug, and serological indexes in multivariable regression model.
ARV, average real variation; CV, coefficient of variation; DBP, diastolic blood pressure; FAI, free androgen index; SBP, systolic blood pressure; SD, standard deviation; SHBG, sex hormone–binding globulin.